B · Normal
[Zhifei Bio: Freeze-dried recombinant RSV vaccine clinical trial application accepted] On November 17, Zhifei Bio (300122.SZ) announced that the freeze-dried recombinant respiratory syncytial virus protein vaccine (CHO cells) developed by the company's wholly-owned subsidiary Zhifei Longkoma has received a drug clinical trial application acceptance notice from the State Food and Drug Administration. The vaccine uses genetic engineering recombinant technology. The active ingredient is recombinant RSV pre-fusion F protein expressed in CHO cells, supplemented by a self-developed new adjuvant. It is suitable for adults to prevent RSV-induced lower respiratory tract infections. As of the date of the announcement, no respiratory syncytial virus vaccine has been approved for marketing in China.
Comments